Sun Pharmaceutical stock initiated with Overweight rating by Morgan Stanley

Morgan Stanley has initiated coverage on Sun Pharmaceutical Industries Ltd. (NS:SUNP) with an Overweight rating and a price target of INR1,960.00. The investment bank cited Sun Pharma’s successful transition from generic to specialty drugs, sector-leading EBITDA margin, and strong balance sheet as key drivers for its past outperformance and earnings upgrade cycle. Morgan Stanley projects an 11% earnings CAGR from fiscal year 2025 to 2027 and approximately 20% average RoCE, underpinned by the company's domestic market leadership and expanding U.S. specialty portfolio, signaling continued outperformance potential.

Analysis

Morgan Stanley has initiated coverage on Sun Pharmaceutical Industries with an 'Overweight' rating and an INR 1,960 price target, underscoring the company's successful pivot from generic to specialty pharmaceuticals. This strategic shift is credited for its earnings upgrade cycle and outperformance against peers over the last five years. The investment bank's bullish thesis is supported by Sun Pharma's sector-leading EBITDA margin, strong return ratios, and a robust balance sheet, which justify a potential multiple re-rating. The company maintains a dominant 8.3% market share in India's domestic branded generic market and is expanding its footprint in the high-value U.S. specialty segment through key products in dermatology, oncology, and ophthalmology, further strengthened by the recent $355 million acquisition of Unloxcyt. Morgan Stanley projects an 11% earnings CAGR for fiscal years 2025-2027, with a sustained average Return on Capital Employed (RoCE) of approximately 20%, signaling a stable and profitable growth outlook.

Key Decisions for Investors

• Given the 'Overweight' rating and projected 11% earnings CAGR through FY27, investors may view this as a positive signal to consider initiating or increasing a position in Sun Pharma as a core holding in the specialty pharmaceutical space.
• Investors should closely monitor the company's ability to maintain its sector-leading EBITDA margins and deliver the forecasted 20% average RoCE, as these metrics are fundamental to Morgan Stanley's valuation thesis.
• The successful integration and commercialization of the recently acquired Unloxcyt, alongside progress in the high-value pipeline including the GLP-1 candidate Utreglutide, represent key catalysts that should be tracked for potential upside.